Gonadotropin-stimulated epidermal growth factor receptor expression in human ovarian surface epithelial cells: involvement of cyclic AMP-dependent exchange protein activated by cAMP pathway

Jung-Hye Choi1,5*, Chien-Lin Chen2,3*, Song Ling Poon1, Hsin-Shih Wang2,4 and Peter C K Leung1

1Department of Obstetrics and Gynecology, British Columbia Research Institute for Children’s and Women’s Health, University of British Columbia, 2H-30, 4490 Oak Street, Vancouver, British Columbia, Canada V6H 3V5
2Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan, ROC
3Center for Traditional Chinese Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ROC
4Department of Obstetrics and Gynecology, Lin-Kou Medical Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ROC
5Department of Oriental Pharmacy, College of Pharmacy, Kyung Hee University, Seoul, South Korea

(Correspondence should be addressed to P C K Leung; Email: peleung@interchange.ubc.ca)

*J-H Choi and C-L Chen contributed equally to this work

Abstract

In addition to their critical roles in folliculogenesis and ovarian granulosa cell steroidogenesis, gonadotropins have been implicated as potential risk factors in ovarian epithelial carcinomas, most of which are derived from ovarian surface epithelium (OSE). However, the molecular mechanism underlying the effects of FSH and LH in OSE and its neoplastic counterpart is not well understood. We previously demonstrated that gonadotropins promote the growth of OSE cells by regulating the levels of epidermal growth factor receptor (EGFR) via the activation of ERK1/2 and PI3K pathways in immortalized human OSE (IOSE) cells. In this study, we investigated whether cAMP and its novel binding target, named exchange protein activated by cAMP (Epac), are involved in the gonadotropin-induced EGFR expression in OSE cells. Gonadotropins elevated intracellular cAMP levels in both IOSE and granulosa cells, and this increase was attenuated by SQ22536, an inhibitor of adenylyl cyclase (AC). The activation of the ERK1/2 and Akt pathways as well as the expression of EGFR was stimulated by reagents that elevate intracellular cAMP levels, via cAMP analog 8-bromo-cAMP and AC activator forskolin. A similar increase was observed when the cells were treated with a novel cAMP analog, 8-(4-chlorophenylthio)-2'-O-methyl adenosine-3',5'-cyclic monophosphate (8-CPT-2ME-cAMP), which activates Epac specifically but not PKA. Moreover, the gonadotropin-induced EGFR expression and ERK1/2 and Akt activation were abolished by overexpression of dominant negative Epac. Taken together, these results indicate that the AC/cAMP/Epac signaling pathway may mediate the up-regulation of EGFR by gonadotropins via ERK1/2 and Akt activation.

Endocrine-Related Cancer (2009) 16 179–188

Introduction

Ovarian cancer is the sixth most common cancer and the fifth leading cause of cancer-related deaths among women in developed countries (Greenlee et al. 2000). Worldwide, the total number of cases is ~ 190 000 per year (Gadducci et al. 2004). About 1 out of 70 women in the United States will develop ovarian cancer (Quirk & Natarajan 2005). Approximately 90% of malignant tumors arise from the ovarian surface epithelium (OSE), a single layer of flat-to-cuboidal epithelial cells covering the ovary (Nicosia & Johnson 1984),
while the rest originate from granulosa cells (~5%) or, rarely, germs cells (~1%). While studies on the ovary have mainly focused on the other cell types such as granulosa and theca cells, which play a critical role in folliculogenesis and steroidogenesis, the OSE was among the least characterized compartments of the ovary. In particular, the cellular and molecular mechanisms by which it undergoes tumor formation and neoplastic progression are not understood.

The etiology of ovarian epithelial cancer (OEC) remains largely unknown. To date, family history of ovarian cancer, age, and nulliparity have been recognized as risk factors of OEC, while pregnancy, oral contraceptive use, hysterectomy, and tubal ligation are protective factors (Holschneider & Berek 2000, Hanna & Adams 2006). There is evidence that several key reproductive hormones including gonadotropins can influence the incidence and/or growth characteristics of ovarian cancer cells (Riman et al. 1998, Gadducci et al. 2004, Lukanova & Kaaks 2005). The gonadotropin hypothesis proposes that excessive levels of gonadotropins, related to the surge occurring during ovulation and the loss of gonadal negative feedback associated with menopause and premature ovarian failure, may play a role in the development and progression of OEC (Biskind & Biskind 1944, Cramer & Welch 1983). In support of this hypothesis, both FSHR and LHR have been found to be expressed in normal OSE cells and ovarian tumors (Lu et al. 2000, Minegishi et al. 2000, Zheng et al. 2000, Parrott et al. 2001, Choi et al. 2002). Numerous studies have suggested that gonadotropin modulates gene expression leading to changes in cell growth, apoptosis, and/or metastasis of OSE as well as ovarian cancer, suggesting the potential involvement of gonadotropins in ovarian cancer development (Konishi 2006). However, the exact molecular mechanism of gonadotropins in OSE and OEC cells is not well characterized.

It has been well demonstrated that the overexpression and aberrant activation of epidermal growth factor receptor (EGFR) are related to tumor development, progression, recurrence, and poor prognosis in numerous cancers (Salomon et al. 1995a,b, Nicholson et al. 2001). In ovarian cancer, EGFR is frequently amplified and/or overexpressed, and a TGFα (or EGF)/EGFR autocrine loop contributes to the cell growth (Owens et al. 1991, Berns et al. 1992, Owens & Leake 1992, Brader et al. 1998, Alper et al. 2000). Elevated expression of EGFR may, therefore, play an important role in tumorigenesis and cancer progression in ovarian epithelium. Despite these observations, the exact mechanism of the regulation of EGFR expression in OSE and its malignant counter part is not clearly understood. In a previous study, we have demonstrated that the treatment with FSH and LH significantly increased *Egr* mRNA and EGFR protein in the immortalized OSE cells (Choi et al. 2005). In addition, IOSE cells co-treated with gonadotropins and EGF revealed a significant stimulation of mitogenesis. These results suggest that an increased level of EGFR induced by gonadotropins in preneoplastic OSE cells may contribute to the uncontrolled growth, as an important driving force for the tumorigenesis. In this regard, it is crucial to understand the molecular mechanism by which gonadotropins increase the levels of EGFR.

Gonadotropin receptors are G-protein-coupled receptors (GPCRs) with seven transmembrane domains. It is generally accepted that the protein kinase A (PKA) pathway mediates the effects of gonadotropins on granulosa cells, such that activation of adenylate cyclase by the stimulatory G-protein, Gs, is followed by a rapid increase in cAMP and a subsequent activation of PKA (Hsueh et al. 1984). Interestingly, growing evidence suggests that FSHR and LHR can activate a number of additional signaling pathways such as protein kinase C (PKC), PI3K, and MAPK in both a cAMP/PKA-dependent and -independent manner in granulosa cells (Pennybacker & Herman 1991, Flores et al. 1992, Cameron et al. 1996, Das et al. 1996, Herrlich et al. 1996, Chiang et al. 1997, Babu et al. 2000, Gonzalez-Robayna et al. 2000, Sekar & Veldhuis 2001, Cunningham et al. 2003, Alam et al. 2004). Moreover, a new binding target of the cAMP named exchange protein directly activated by cAMP (Epac) has been recently identified (Kawasaki et al. 1998, de Rooij et al. 1998), which may also be implicated in gonadotropin actions. Previously, we have demonstrated that gonadotropins up-regulate EGFR expression through the activation of the ERK1/2 and PI3K pathways, but not PKA, in IOSE cells (Choi et al. 2005). In the present study, we investigated whether cAMP and/or Epac is involved in the gonadotropin-induced EGFR in IOSE cells.

### Materials and methods

#### Material

Human LH and recombinant FSH were provided by Dr A F Parlow (National Hormone and Pituitary Program, Harbor–University of California Los Angeles Medical Center, Torrance, CA, USA). 8-Br-cAMP (8-bromoadenosine 4, 5-cyclic monophosphate), 8-CPT-2ME-cAMP (8-(4-chloro-phenylthio)-2′-O-methyladenosine-3′,5′-cyclic monophosphate), SQ22536...
(9-(tetrahydro-2-furanyl)-9H-purin-6-amine), EGTA (ethylene-bis (oxyethyl enenitrilo) tetraacetic acid), BAPTA-AM (1,2-bis(2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid tetrakis (acetoxymethyl ester)), and forskolin were purchased from Sigma. Antibody against EGFR and β-actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Phospho ERK1/2 and Akt were obtained from Cell Signaling Technology (Beverly, MA, USA). Antibody against Epac was purchased from Gene Tex Incorporation (San Antonio, TX, USA).

**Cell culture**

Following follicular aspirates that were collected during oocyte retrieval from women undergoing IVF, SVOG-4M human granulosa luteal cells (hGLC) were prepared as previously described (Peng et al. 1994). Non-tumorigenic SV40 tag-immortalized OSE-derived cells (IOSE-80, IOSE-80PC, and IOSE-120) were cultured as previously described (Choi et al. 2001) in medium 199:MCDB 105 (1:1; Sigma–Aldrich Corp.) containing 10% fetal bovine serum (Hyclone Laboratories Ltd, Logan, UT, USA), 100 U/ml penicillin G, and 100 μg/ml streptomycin (Life Technologies Inc.) in a humidified atmosphere of 5% CO2–95% air at 37 °C. At confluency, the cells were passaged with 0.06% trypsin (1:250)/0.01% EDTA in Mg2+/Ca2+-free Hank’s buffered salt solution (HBSS).

**ELISA for intracellular cAMP**

To measure intracellular cAMP levels, IOSE and SVOG-4M cells (1 × 10^4 cells/well) were plated onto 96-well microplates and cultured for 24 h. The cells were then pre-incubated in serum-free medium for 30 min and treated with FSH or LH for 0, 5, or 15 min. Intracellular cAMP levels were measured using a cAMP Biotrak enzyme immunoassay system (Amersham Pharmacia Biotech), according to the manufacturer’s suggested procedure.

**Cell transfection**

Dominant negative Epac (DN-Epac) mutant Epac-R279E was generously provided by Dr X Cheng (Department of Pharmacology and Toxicology, University of Texas Medical Branch). DN-Epac vector or empty vector was transfected into IOSE cells using FuGENE 6 (Roche Applied Science) according to the manufacturer’s suggested protocol at 50% confluence on six-well plates. The transfected cells were grown for 24 h and used for further experiments (Fig. 6).

**Immunoblot analysis**

The cells were seeded at a density of 2 × 10^5 cells in 35 mm culture dishes and cultured. The cells were washed once with medium, and serum starved for at least 2 h prior to treatments with sample. The cells were washed twice with ice-cold PBS and lysed in ice-cold radioimmuno precipitation assay (RIPA) buffer (150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 50 mM Tris (pH, 7.5), 1 mM phenylmethyl-sulphonyl fluoride, 10 μg/ml leupeptin, and 100 μg/ml aprotinin). The extracts were placed on ice for 15 min and centrifuged to remove cellular debris. The protein concentration of supernatants was determined using the Bradford assay (Bio-Rad Laboratories). Thirty microgram of total protein was run on 10% SDS-polyacrylamide gels and electrotransferred to a nitrocellulose membrane (Amersham Pharmacia Biotech). The membrane was immunobotted using specific primary antibodies at 4 °C overnight. After washing, the signals were detected with HRP-conjugated secondary antibody for 1 h, and visualized using the ECL chemiluminescent system (Amersham Pharmacia Biotech).

**Rap1 activation assay**

Rap1 activity was detected by a Rap1 activation assay kit (Upstate Biotechnology Inc., Lake Placid, NY, USA) following the manufacturer’s instructions. Briefly, cells were lysed with 1 ml lysis buffer and Rap1–GTP were pulled down using the glutathione S-transferase fusion protein corresponding to human RBD of RalGDS bound to agarose. The agarose beads were washed with ice-cold lysis buffer thrice, and bound proteins were eluted in 40 μl 2X SDS sample buffer. Immunoblot (see above) was performed with anti-Rap1 (Upstate Biotechnology) antibody.

**Results**

**Effect of FSH and LH on intracellular cAMP levels**

Considering that gonadotropins have shown to stimulate a cAMP-independent pathway in several cell systems, we investigated whether the OSE cells can respond to gonadotropin stimulation by increasing cAMP levels as do granulosa cells. Three immortalized ovarian surface epithelial cells (IOSE-80, IOSE-120, and IOSE-80PC) and one immortalized hGLC (SVOG-4M) were treated with FSH or LH, and then cAMP levels were measured using ELISA. As shown in Fig. 1, FSH and LH induced a four- to sixfold increase of intracellular cAMP levels in SVOG-4M cells which was used as a positive control. All three IOSE cells had
comparable or slightly increased basal levels of cAMP when compared with SVOG-4M cells. Treatment with FSH or LH for 15 min substantially stimulated the cAMP levels in IOSE cells, although the stimulatory effect was less potent than that in SVOG-4M cells.

Involvement of increased cAMP in gonadotropin-induced EGFR up-regulation

We have previously shown that gonadotropins up-regulate the EGFR through the activation of the ERK1/2 and PI3K pathways in IOSE-80 and IOSE-80PC cells (Choi et al. 2005). IOSE-80PC, a post-crisis cell line originally generated from IOSE-80, showed similar EGFR mRNA and protein expressions as IOSE-80 cells. Subsequently, further experiments were performed using IOSE-80PC to evaluate the mechanism of gonadotropins on the expression of EGFR. To evaluate whether the gonadotropin-induced cAMP levels was involved in the modulation of gonadotropin-induced EGFR expression in IOSE-80PC cells, cAMP analog 8-Br-cAMP (0.5 mM) and an adenylate cyclase activator forskolin (10 μM) were used to investigate the activation of ERK1/2, Akt and the expression level of EGFR. Figure 2 demonstrated that 8-Br-cAMP or forskolin enhanced the phosphorylation of ERK1/2 and Akt (Fig. 2, data shown for three independent paired experiments, lanes 1 vs 4, 2 vs 5, and 3 vs 6). In addition, treatment with forskolin or 8-Br-AMP for 24 h increased EGFR protein level in the IOSE cells (Fig. 3).

Several studies have suggested that gonadotropins play a role in proliferation and steroidogenesis through a cAMP-dependent or -independent increase in intracellular calcium ion levels in a number of cell systems. Using extracellular and intracellular calcium chelators, EGTA and BAPTA-AM respectively, we evaluated the possible involvement of intracellular calcium ion in the gonadotropin-increased EGFR expression in IOSE-80 and IOSE80-PC cells. Neither of calcium ion chelators significantly inhibited the changes in EGFR expression induced by gonadotropins. By contrast, pretreatment with an adenylate cyclase inhibitor SQ22536 markedly blocked the stimulatory effect of gonadotropins on EGFR expression (Fig. 4).

Effect of Epac-specific cAMP analog on the activation of ERK1/2 and Akt and expression of EGFR

In the previous study, we failed to demonstrate the involvement of PKA pathway in the gonadotropin-induced EGFR up-regulation in IOSE cells (Choi et al. 2005). In this regard, it seems reasonable to examine a new target of cAMP, Epac, also known as ‘cAMP guanine nucleotide exchange factors’ (cAMP-GEFs; Kawasaki et al. 1998, de Rooij et al. 1998). First, using immunoblot analysis, we demonstrated the basal expression of Epac in all three IOSE cells (Fig. 5A). To investigate whether gonadotropins- or cAMP-induced systems.
EGFR up-regulation is associated with Epac, the IOSE cells were treated with a new cAMP analog, 8-(4-chloro-phenylthio)-2'-O-methyladenosine-3',5'-cyclic monophosphate (8-CPT-2ME-cAMP), which specifically activates Epac, but not PKA. As shown in Fig. 5B, treatment with 8-CPT-2ME-cAMP analog induced an increase in phosphorylated ERK1/2 and Akt within 5 min in IOSE cells. The level of phosphorylated Akt reached the maximum at 15 min, followed by a decline evident at 30 min. The activated ERK1/2 declined to the control at 30 min while the activated Akt was still competitive compared with 0 min. Similarly, the Epac-specific cAMP analog increased EGFR expression in a time-dependent manner (Fig. 5C).

**Effect of Epac on the gonadotropin-induced EGFR up-regulation**

Transient transfection with dominant negative Epac (DN-Epac) vector was performed to evaluate whether Epac is involved in response to gonadotropins in IOSE cells. Rap-1 activation assay showed that treatment with FSH or LH for 15 and 30 min activates Rap1, a downstream target of Epac in empty vector-transfected cells while the gonadotropin effect was abolished in DN-Epac-expressing IOSE cells. In addition, the Epac-mutant inhibited the gonadotropin-induced ERK1/2 and Akt activation (Fig. 6A). These observations showed that the cAMP–Epac–Rap1 pathway mediates gonadotropins effect and the expression of Epac mutant biologically inhibits Epac activity in IOSE cells. Furthermore, EGFR was significantly enhanced in empty vector-transfected IOSE cells but not in DN-Epac-transfected IOSE cells after treatment with FSH or LH (100 ng/ml) for 24 h (Fig. 6B). These results suggest that Epac mediates the gonadotropin-induced EGFR expression in IOSE cells.

**Discussion**

Until recently, the cAMP/PKA is generally recognized as the major signaling pathway mediating gonadotropin actions in the ovary. However, increasing evidence over the past few years has implicated the involvement of additional second messengers such as PKC, PI3K, and MAPK in FSHR and LHR signaling in granulosa cells (Pennybacker & Herman 1991, Flores et al. 1992, Cameron et al. 1996, Das et al. 1996, Herrlich et al. 1996, Chiang et al. 1997, Babu et al. 2000, Gonzalez-Robayna et al. 2000, Sekar & Veldhuis 2001, Cunningham et al. 2003, Alam et al. 2004).
In addition to their essential role within the ovarian follicles, gonadotropins also exert direct effects in OSE and OEC cells. However, the exact mechanism underlying the actions of gonadotropins in OSE and OEC cells is not understood.

Recently, we have demonstrated that treatment of IOSE cells with gonadotropins increased the expression of EGFR, resulting in an enhanced stimulation of mitogenesis in presence of EGF (Choi et al. 2005). Moreover, the stimulatory effect was mediated by the activation of the PI3K and ERK1/2 pathways, but not by PKA pathway which is a classical binding target of gonadotropin-induced cAMP. This finding suggests the involvement of another second messenger such as intracellular calcium ion and/or an alternative binding target of cAMP in the gonadotropin signaling in OSE cells. In this study, we found that gonadotropin-induced EGFR expression is not dependent on the stimulation of calcium influx, but mediated by the activation of adenylyl cyclase followed by an increase in cAMP levels. We also demonstrated, for the first time, that the novel target of cAMP, Epac, is expressed in IOSE and ovarian cancer cells, and Epac may well mediate the gonadotropin-induced activation of the ERK1/2 and Akt, resulting in EGFR up-regulation in IOSE-cells. The effect of gonadotropins on EGFR expression appears to be more potent in normal or early stages of cancers which may have low basal EGFR levels (Choi et al. 2005). In addition, IOSE-80 cells treated with gonadotropins and EGF exhibited an additive stimulation of mitogenesis. These findings indicate that gonadotropins can stimulate EGFR expression in OSE during menopause, and this effect is associated with the initiation of the ovarian cancer because postmenopausal women have high gonadotropin levels in their serum. Thus, the understanding of the regulatory mechanism of EGFR expression in OSE may provide important insights into the mechanism that controls a response of OSE to EGF and/or TGFα through the modulation of its receptor levels.

Numerous reports have demonstrated that binding of gonadotropins to their receptors can increase inositol phosphate and accumulate intracellular calcium in granulosa cells (Veldhuis 1987, Flores et al. 1990, Gilchrist et al. 1996, Hirsch et al. 1996). Coupling of activated LHR to the Gi subunit stimulated PLC to synthesize inositol-1,4,5-triphosphate (IP3) and diacylglycerol, resulting in the elevation of intracellular calcium ion levels and activation of PKC (Herrlich et al. 1996, Flores et al. 1998, Kuhn & Gudermann 1999). In addition, it is of interest that FSHR-3, which is an alternate splicing variant of FSHR containing growth type-1 receptor motif, leads to a cAMP-independent but calcium-dependent ERK1/2 activation (Babu et al. 2000, Touyz et al. 2000). In the present study, we have demonstrated that cAMP, but not calcium, is associated with gonadotropin-induced EGFR up-regulation. However, whether

![Figure 6 Effect of dominant negative Epac on (A) gonadotropin-induced ERK1/2 and Akt activation and (B) EGFR up-regulation. Following transient transfection of cells with DN-Epac or empty vector control for 24 h, the cells were treated with 100 ng/ml FSH or LH for 15 min. The activation of ERK1/2 and Akt was evaluated by immunoblot analysis using phospho-ERK1/2 and Akt antibody. The activity of Rap1 was determined using RaLGDs–Rap1-binding domain (RBD) as an activation-specific probe and subsequently quantified by Immunoblot analysis (Rap1–GTP). To ensure that equal amounts of protein were analyzed, Rap1 levels were determined in whole cell lysates. (A) Vector control or DN-Epac-transfected IOSE cells were treated with 100 ng/ml FSH or LH for 24 h, and (B) the expression of EGFR was evaluated by immunoblot analysis using EGFR antibody.](image-url)
calcium-dependent pathway can mediate other response to the gonadotropins in IOSE cells remains to be elucidated.

Recently, the MAPK and PI3K have been recognized as two major downstream kinases of cAMP. For example, studies performed in the rat (Das et al. 1996, Gonzalez-Robayna et al. 2000) and pig (Cameron et al. 1996) granulose cells and human luteinized granulosa cells (Dewi et al. 2002) have demonstrated that FSH and LH stimulate the activation of ERK1/2 and/or p38, the two members of the MAPK family, in a cAMP/PKA-dependent manner. Moreover, with the identification of a new class of cAMP-binding proteins, there is a growing body of evidence for cAMP-dependent but PKA-independent kinase activation (Kawasaki et al. 1998, de Rooij et al. 1998). This protein, named exchange proteins directly activated by cAMP (Epac) and also known as ‘cAMP guanine nucleotide exchange factors’ (cAMP-GEFs), is activated by cAMP, Gonzalez-Robayna et al. found that FSH and cAMP analogs activate Akt and PI3K inhibitor LY294002, but not PKA inhibitor H89 inhibits this activation. By contrast, the expression and activation of Sgk, which is a serum- and glucocorticoid-inducible kinase and associated with proliferative stages of granulosa cell, were regulated by the PI3K and p38 MAPK. Thus, it was speculated that Epac might be responsible for the cAMP-mediated phosphorylation of Akt and Sgk via PI3K, while PKA is obligatory for the transcription of Sgk in granulosa cells. Furthermore, the Epac might be related to LH-stimulated progesterone production in hGLC. In hGLC, treatment with 8-CPT-2 ME-cAMP, the cAMP-GEF-specific cAMP analog that does not react with PKA, increased progesterone synthesis and secretion in a dose-dependent manner (Chin & Abayasekara 2004). These observations are in accordance with our finding that involvement of Epac in the gonadotropin- and cAMP-induced ERK1/2 and Akt activation in IOSE cells. However, the mechanism by which Epac regulates ERK1/2 and Akt in IOSE cells remains unclear. It is accepted that Epac controls small GTPases, such as Rap1 (Kawasaki et al. 1998, de Rooij et al. 1998). The GTPase stimulates Raf and/or Ras kinase and leads to the activation of the PI3K/Akt and MAPK pathways, suggesting that gonadotropin-induced activation of ERK1/2 and Akt might be mediated by the cAMP/Epac/Rap1/Ras (or Raf) pathway (Gonzalez-Robayna et al. 2000, Gao et al. 2006). In addition, a study suggested that an interaction between T cell leukemia 1 and Epac1 regulates the activation and distribution of Akt (Misra et al. 2008).

Interestingly, inhibition of Epac activation by DN-Epac, by itself, did not show any mitogenic change in IOSE cells while the treatment of DN-Epac transfected IOSE cells with gonadotropins induced a decrease in cell proliferation. This result suggests that stimulation by gonadotropins is required for Epac-mediated cell proliferation as well as EGFR expression.

It is noteworthy that 8-CPT-2ME-cAMP induced phosphorylation of ERK1/2 and Akt within 5 min with the decrease of their level at 15 min and 30 min respectively (Fig. 5B). Similarly, we had demonstrated that treatment with gonadotropins induced a significant increase in the phosphorylated form of ERK1/2 and Akt at 5 min, and the activated ERK1/2 and Akt began to decline at 15–60 min in IOSE cells. These results indicate that 8-CPT-2ME-cAMP can mimic the pattern of gonadotropin-induced signaling in IOSE cells and the activation of ERK1/2 and Akt at 5–30 min may play a critical role in gonadotropin-regulated EGFR expression.

In ovarian cancer cells, cAMP has been shown to mediate integrin-dependent adhesion of OVCAR-3 cells to fibronectin through the Epac (Rangarajan et al. 2003). It is of note that our immunoblot analysis revealed that Epac protein is highly expressed in IOSE cells, while it is hardly detectable in ovarian cancer cells including OVCAR-3 cells (Data not shown). Further experiments will be warranted to evaluate whether the significant change in Epac expression from premalignant IOSE cells to its neoplastic counterpart is associated with differential responses to gonadotropins stimulation in OSE and ovarian cancer cells. Moreover, we have previously found that the stimulatory effect of gonadotropins on invasion in ovarian cancer cells involve the PKA and PI3K pathways (Choi et al. 2006). Some studies suggested that the PKA via the IL-6/STAT3 pathway mediates gonadotropin-induced proliferation of OSE and ovarian cancer cells (Syed et al. 2001, 2002). Treatment of OEC cells with FSH significantly increased the levels of PKCζ mRNA and protein, suggesting that the stimulation of PKCζ is involved in FSH-induced cell proliferation (Ohtani et al. 2001). Taken together, these observations suggest that gonadotropin-induced cAMP levels stimulate the activation of both PKA-dependent and -independent signaling pathways, resulting in diverse biological roles of gonadotropins in OSE and its neoplastic counterpart.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

www.endocrinology-journals.org
J-H Choi, C-L Chen et al.: Action of gonadotropins on EGFR expression

**Funding**

This work was supported by the Canadian Institutes of Health Research. PCKL is the recipient of a Distinguished Scholar Award from the Child and Family Research Institute. JHC and SLP were recipients of Studentship Awards from the Interdisciplinary Women’s Reproductive Health Research Training Program. Dominant negative Epac mutant Epac-R279E was generously provided by Dr X. Cheng (Department of Pharmacology and Toxicology, University of Texas Medical Branch).

**Acknowledgements**

We are thankful to Dr Auersperg (University of British Columbia, Vancouver, BC) and Dr Andrew Godwin (Fox Chase Cancer Center, Philadelphia, PA) for providing IOSE-80PC cell lines.

**References**

Alam H, Maizels ET, Park Y, Ghaey S, Feiger ZJ, Chandel NS & Hunzicker-Dunn M 2004 Follicle-stimulating hormone activation of hypoxia-inducible factor-1 by the phosphatidylinositol 3-kinase/AKT/Ras homolog enriched in brain (Rheb)/mammalian target of rapamycin (mTOR) pathway is necessary for induction of select protein markers of follicular differentiation. *Journal of Biological Chemistry* **279** 19431–19440.


Flores JA, Veldhuis JD & Leong DA 1990 Follicle-stimulating hormone evokes an increase in intracellular free calcium ion concentrations in single ovarian (granulosa) cells. *Endocrinology* **127** 3172–3179.


Kuhn B & Gudermann T 1999 The luteinizing hormone receptor activates phospholipase C via preferential coupling to Gi2. *Biochemistry* **38** 12490–12498.


